J Gynecol Oncol.  2013 Jul;24(3):212-214. 10.3802/jgo.2013.24.3.212.

Updates of the current screening guidelines for the early detection of cervical cancer

• Hong JH
• Lee JK

• KMID: 2288526
• DOI: http://doi.org/10.3802/jgo.2013.24.3.212

Abstract

No abstract available.

MeSH Terms

Mass Screening
Uterine Cervical Neoplasms

Reference

1. Lee JK, Hong JH, Kang S, Kim DY, Kim BG, Kim SH, et al. Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol. 2013; 24:186–203.

2. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007; 197:346–355.

3. Partridge EE, Abu-Rustum NR, Campos SM, Fahey PJ, Farmer M, Garcia RL, et al. Cervical cancer screening. J Natl Compr Canc Netw. 2010; 8:1358–1386.

4. Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156:880–891.

5. Institute for Clinical System Improvement. Initial management of abnormal cervical cytology (Pap test) and HPV test in adult and adolescent females. Bloomington, MN: Institute for Clinical System Improvement;2013. cited 2013 Mar 19. Available from: https//www.icsi.org/_asset/hks01y/AbPap-Interact0910.pdf.

6. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013; 17:5 Suppl 1. S1–S27.

7. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62:147–172.

8. Huang A, Quinn M, Tan J. Outcome in women with no endocervical component on cervical cytology after treatment for high-grade cervical dysplasia. Aust N Z J Obstet Gynaecol. 2009; 49:426–428.

9. Davey DD, Cox JT, Austin RM, Birdsong G, Colgan TJ, Howell LP, et al. Cervical cytology specimen adequacy: Updated patient management guidelines. J Low Genit Tract Dis. 2008; 12:71–81.

10. Elumir-Tanner L, Doraty M. Management of Papanicolaou test results that lack endocervical cells. CMAJ. 2011; 183:563–568.

11. Siebers AG, Klinkhamer PJJM, Vedder JEM, Arbyn M, Bulten J. Causes and relevance of unsatisfactory and satisfactory but limited smears of liquid-based compared with conventional cervical cytology. Arch Pathol Lab Med. 2012; 136:76–83.

12. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011; 135:468–475.

13. Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev. 2013; 3:CD008054.

14. Benard VB, Watson M, Castle PE, Saraiya M. Cervical cancer rates among young females in the United States. Obstet Gynecol. 2012; 120:1117–1123.

15. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med. 2008; 168:1881–1889.